Nanoparticulate medicines offer the advantage of allowing delivery of large quantities of unmodified drug within the same particle. Nanoparticle uptake by cancer cells can, however, be compromised due to the large size and hydrophilicity of the particle. To circumvent cell penetration problems and simultaneously improve tumor specificity, nanoparticulate medicines have been linked to targeting ligands that bind to malignant cell surfaces and enter cells by receptor-mediated endocytosis. In this chapter, we summarize multiple methods for delivering nanoparticles into cancer cells by folate receptor-mediated endocytosis, devoting special emphasis to folate-targeted liposomes. Folate receptor-mediated endocytosis has emerged as an attractive strategy for nanoparticle delivery due to both overexpression of the folate receptor on cancer cells and the rapid internalization of the receptor by receptor-mediated endocytosis.
Affiliation(s): (1) Department of Chemistry and Purdue Cancer Center, Purdue University, West Lafayette, IN, USA
Book Title: Cancer Nanotechnology: Methods and Protocols
Series: Methods in Molecular Biology | Volume: 624 | Pub. Date: May-01-2010 | Page Range: 249-265 | DOI: 10.1007/978-1-60761-609-2_17
Subject: Cancer Research
Key Words: Folate receptor-targeted drugs - cancer nanomedicines - ligand-targeted nanoparticles - folate-targeted imaging agents - folic acid coupling chemistries - pteroic acid synthesis - conjugation of amine, hydroxyl, thiol, or carboxyl functionalized nanoparticles to folate